Frequently searched
↑ ↓ to move · Enter to open · Esc to closeSynonyms and typos are matched
Trial site
Recruiting
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
NCT07185256· Phase 1/2· Opus Genetics, Inc· Source
Contact: Hailey Ahrens
Site data: ClinicalTrials.govUpdated 12 Nov 2026
Report an error